Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Capital Expenditures (2016 - 2025)

Veracyte's Capital Expenditures history spans 14 years, with the latest figure at -$3.6 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 186.67% year-over-year to -$3.6 million; the TTM value through Dec 2025 reached $2.3 million, down 79.55%, while the annual FY2025 figure was $2.3 million, 79.55% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$3.6 million at Veracyte, down from $5.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $7.4 million in Q3 2023 and bottomed at -$6.7 million in Q4 2022.
  • The 5-year median for Capital Expenditures is $1.5 million (2021), against an average of $1.2 million.
  • The largest YoY upside for Capital Expenditures was 1518.08% in 2022 against a maximum downside of 1949.58% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $361000.0 in 2021, then tumbled by 1949.58% to -$6.7 million in 2022, then surged by 137.4% to $2.5 million in 2023, then skyrocketed by 65.84% to $4.1 million in 2024, then crashed by 186.67% to -$3.6 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Capital Expenditures are -$3.6 million (Q4 2025), $5.4 million (Q3 2025), and -$1.3 million (Q2 2025).